Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWF0 | ISIN: US87990A1060 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
0,634 US-Dollar
+17,37 % +0,094
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TENAYA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TENAYA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TENAYA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln
30.05.Tenaya Therapeutics, Inc. - 8-K, Current Report6
16.05.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)194SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
13.05.Tenaya Therapeutics, Inc.: Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting6
07.05.Tenaya Therapeutics GAAP EPS of -$0.246
07.05.Tenaya Therapeutics, Inc. - 10-Q, Quarterly Report4
07.05.Tenaya Therapeutics, Inc. - 8-K, Current Report4
25.04.H.C. Wainwright maintains Buy on Tenaya Therapeutics stock8
24.04.Tenaya reports progress in ARVC gene therapy study5
24.04.Tenaya berichtet über Fortschritte in der Gentherapie-Studie für ARVC8
24.04.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Interim Data from RIDGE Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 20254
18.04.Tenaya Therapeutics, Inc. - 8-K, Current Report5
31.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting168TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with...
► Artikel lesen
28.03.Tenaya Therapeutics, Inc. - 8-K, Current Report4
25.03.Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March9
24.03.Tenaya reports promising gene therapy for heart condition5
24.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models306SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
21.03.Tenaya Therapeutics announces $300M mixed shelf offering; shares down7
19.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session174SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
13.03.Canaccord cuts Tenaya Therapeutics price target to $68
11.03.H.C. Wainwright cuts Tenaya Therapeutics price target to $510
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1